112 related articles for article (PubMed ID: 9518009)
1. Clinical predictors of azole resistance, outcome and survival from oesophageal candidiasis in AIDS patients.
Laing RB; Brettle RP; Leen CL
Int J STD AIDS; 1998 Jan; 9(1):16-20. PubMed ID: 9518009
[TBL] [Abstract][Full Text] [Related]
2. Rationalizing prescribing for oral and oesophageal candidiasis.
Taylor CB; Finlay R; Richardson C; Bunting P; Welch J
Int J STD AIDS; 1996 Oct; 7(6):452. PubMed ID: 8940678
[No Abstract] [Full Text] [Related]
3. Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression.
Walmsley S; King S; McGeer A; Ye Y; Richardson S
Clin Infect Dis; 2001 Jun; 32(11):1554-61. PubMed ID: 11340526
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS.
Laine L; Rabeneck L
Aliment Pharmacol Ther; 1995 Oct; 9(5):553-6. PubMed ID: 8580277
[TBL] [Abstract][Full Text] [Related]
5. Azole drug resistance in yeasts.
Johnson EM; Warnock DW
J Antimicrob Chemother; 1995 Nov; 36(5):751-5. PubMed ID: 8626255
[No Abstract] [Full Text] [Related]
6. Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients.
Barchiesi F; Giacometti A; Arzeni D; Branchesi P; Crescenzi G; Ancarani F; Scalise G
J Chemother; 1992 Dec; 4(6):381-6. PubMed ID: 1287140
[TBL] [Abstract][Full Text] [Related]
7. Can we prevent azole resistance in fungi?
Denning DW
Lancet; 1995 Aug; 346(8973):454-5. PubMed ID: 7637473
[No Abstract] [Full Text] [Related]
8. [Diagnosis, treatment and prevention of infections caused by fungi in HIV-positive patients].
Fortun Abete J
Rev Clin Esp; 1995 Oct; 195 Suppl 3():4-14. PubMed ID: 9441305
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.
Vazquez JA; Skiest DJ; Tissot-Dupont H; Lennox JL; Boparai N; Isaacs R
HIV Clin Trials; 2007; 8(2):86-97. PubMed ID: 17507324
[TBL] [Abstract][Full Text] [Related]
10. [Antifungal susceptibility for Candida albicans isolated from AIDS patients with oropharyngeal and esophageal candidiasis: experience with Etest].
Tapia C; González P; Pereira A; Pérez J; Noriega LM; Palavecino E
Rev Med Chil; 2003 May; 131(5):515-9. PubMed ID: 12879812
[TBL] [Abstract][Full Text] [Related]
11. Resolution of azole-resistant oesophageal candidiasis in an AIDS patient after treatment with caspofungin.
Smith K; Youle M; Baker B; Ballinger J; Cuthbertson Z; Johnson M
AIDS; 2003 Feb; 17(3):448-9. PubMed ID: 12556703
[No Abstract] [Full Text] [Related]
12. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients.
Veroux M; Macarone M; Fiamingo P; Cappello D; Gagliano M; Di Mare M; Vizcarra D; Spataro M; Giuffrida G; Sorbello M; Severino V; Veroux P
Transplant Proc; 2006 May; 38(4):1037-9. PubMed ID: 16757256
[TBL] [Abstract][Full Text] [Related]
13. Invasive oesophageal candidiasis: current and developing treatment options.
Vazquez JA
Drugs; 2003; 63(10):971-89. PubMed ID: 12699400
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of candidiasis and cryptococcosis in AIDS].
Just-Nübling G
Mycoses; 1994; 37 Suppl 2():56-63. PubMed ID: 7609745
[TBL] [Abstract][Full Text] [Related]
15. Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group.
de Repentigny L; Ratelle J
Chemotherapy; 1996; 42(5):374-83. PubMed ID: 8874977
[TBL] [Abstract][Full Text] [Related]
16. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis.
Vazquez JA; Schranz JA; Clark K; Goldstein BP; Reboli A; Fichtenbaum C
J Acquir Immune Defic Syndr; 2008 Jul; 48(3):304-9. PubMed ID: 18545153
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole for azole-refractory candidiasis in patients with HIV infection.
Winslow DL
AIDS Alert; 2007 May; 22(5):59-60. PubMed ID: 17577961
[No Abstract] [Full Text] [Related]
18. [Antifungal agent resistance of yeasts of clinical significance].
Odds FC
Rev Clin Esp; 1995 Oct; 195 Suppl 3():56-7. PubMed ID: 9441307
[No Abstract] [Full Text] [Related]
19. Resistant candidiasis.
Powderly WG
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):925-9. PubMed ID: 7811544
[TBL] [Abstract][Full Text] [Related]
20. Candidiasis in immune-compromised women.
Cadman J
GMHC Treat Issues; 1997; 11(7-8):18. PubMed ID: 11364644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
